Opipramol
PreclinicalSmall molecule
Opipramol is one of 9 small molecule programs targeting Bruxism. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Bruxism
#DrugCompanyPhaseTrials
1Botox
RRevance Therapeutics, Inc.
Approved
Advil
KKenvue Brands
Approved
Paraflex
WWim Janssens
Approved
Botox
AbbViePreclinical
Pharmacotherapy
UUniversity of Pittsburgh
Preclinical
Dysport
GGalderma R&D
Preclinical
Opipramol
WWroclaw Medical University
Preclinical
Prabotulinumtoxina
UUniversity of Southern California
Preclinical
Gabapentine
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Opipramol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- WWroclaw Medical University